HC Wainwright Brokers Decrease Earnings Estimates for MIST

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Analysts at HC Wainwright decreased their FY2028 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Friday, March 20th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.45 per share for the year, down from their previous forecast of $0.53. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $0.92 EPS and FY2030 earnings at $1.70 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Friday, March 20th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $37.52 million.

MIST has been the subject of several other research reports. Zacks Research cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company increased their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Finally, Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Milestone Pharmaceuticals Stock Down 7.4%

MIST stock opened at $1.26 on Monday. The company’s 50 day moving average price is $1.79 and its 200 day moving average price is $1.99. The firm has a market capitalization of $107.31 million, a price-to-earnings ratio of -1.59 and a beta of 0.48. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MIST. Sapient Capital LLC acquired a new stake in Milestone Pharmaceuticals during the 3rd quarter worth $25,000. Strategic Family Wealth Counselors L.L.C. acquired a new position in Milestone Pharmaceuticals in the fourth quarter valued at $25,000. Eaton Financial Holdings Company LLC purchased a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth about $26,000. Bank of America Corp DE grew its holdings in shares of Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the last quarter. Finally, Stephenson & Company Inc. acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth about $40,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Insiders Place Their Bets

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 34,523 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39. Following the sale, the chief executive officer owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 113,693 shares of company stock worth $233,347 over the last 90 days. 19.50% of the stock is currently owned by company insiders.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.